Santhera Confident Of Raxone DMD Success Despite Setbacks

Santhera Pharmaceuticals AG is still convinced that there is a future for Raxone (idebenone) as a treatment for Duchenne muscular dystrophy (DMD) despite repeated knockbacks from European regulators, as sales of the drug in its already-approved indication of Leber’s hereditary optic neuropathy (LHON) continue to climb.

The Swiss drugmaker has had a tough time to date in its talks with the European Medicines Agency with the latter's evaluation committee, the CHMP, initially rejecting Santhera’s request for the DMD indication in September 2017